Tasosartan

From Wikipedia, the free encyclopedia

Tasosartan

Systematic (IUPAC) name
2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
Clinical data
Pregnancy cat.	N/A
Legal status	Withdrawn
Identifiers
CAS number	145733-36-4^Y
ATC code	C09CA05
PubChem	CID 60919
DrugBank	DB01349
ChemSpider	54890^N
UNII	48G92V856H^Y
Chemical data
Formula	C₂₃H₂₁N₇O
Mol. mass	411.459 g/mol
N (what is this?) (verify)

Tasosartan is an angiotensin II receptor antagonist.

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.^[1]^[2]

References

↑ Atkinson AJ et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 0-12-369417-5.
↑ Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm 57 (13): 1231–41. PMID 10902066.

Antihypertensives: agents acting on the renin–angiotensin system (C09)

ACE inhibitors
("-pril")

Sulfhydryl-containing: Captopril
Zofenopril

Dicarboxylate-containing: Enalapril^#
Ramipril
Quinapril (+HCT)
Perindopril
Lisinopril (+HCT)
Benazepril

Phosphonate-containing: Fosinopril (+HCT)

AIIRAs/
("-sartan")

Renin inhibitors/
("-kiren")

Aliskiren (+amlodipine, +amlodipine and HCT)
Remikiren^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

M: VAS

anat (a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot

noco/syva/cong/lyvd/tumr, sysi/epon, injr

proc, drug (C2s+n/3/4/5/7/8/9)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.